Zolla-Pazner S - Search Results

1

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, Zolla-Pazner S. Gorny MK, et al. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3238-42. doi: 10.1073/pnas.88.8.3238. Proc Natl Acad Sci U S A. 1991. PMID: 2014246 Free PMC article.

2

Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.

Karwowska S, Gorny MK, Buchbinder A, Gianakakos V, Williams C, Fuerst T, Zolla-Pazner S. Karwowska S, et al. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1099-106. doi: 10.1089/aid.1992.8.1099. AIDS Res Hum Retroviruses. 1992. PMID: 1380257

3

Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.

McKeating JA, Thali M, Furman C, Karwowska S, Gorny MK, Cordell J, Zolla-Pazner S, Sodroski J, Weiss RA. McKeating JA, et al. Virology. 1992 Sep;190(1):134-42. doi: 10.1016/0042-6822(92)91199-5. Virology. 1992. PMID: 1382339

4

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S. Gorny MK, et al. J Virol. 1992 Dec;66(12):7538-42. doi: 10.1128/JVI.66.12.7538-7542.1992. J Virol. 1992. PMID: 1433529 Free PMC article.

5

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Buchbinder A, Zolla-Pazner S, Karwowska S, Gorny MK, Burda ST. Buchbinder A, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1395. doi: 10.1089/aid.1992.8.1395. AIDS Res Hum Retroviruses. 1992. PMID: 1466965 No abstract available.

6

Passive immunization for the prevention and treatment of HIV infection.

Zolla-Pazner S, Gorny MK. Zolla-Pazner S, et al. AIDS. 1992 Nov;6(11):1235-47. doi: 10.1097/00002030-199211000-00001. AIDS. 1992. PMID: 1472330 No abstract available.

7

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Buchbinder A, Karwowska S, Gorny MK, Burda ST, Zolla-Pazner S. Buchbinder A, et al. AIDS Res Hum Retroviruses. 1992 Apr;8(4):425-7. doi: 10.1089/aid.1992.8.425. AIDS Res Hum Retroviruses. 1992. PMID: 1599752 No abstract available.

8

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ. Tyler DS, et al. J Immunol. 1990 Nov 15;145(10):3276-82. J Immunol. 1990. PMID: 1700004

9

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Xu JY, et al. J Virol. 1991 Sep;65(9):4832-8. doi: 10.1128/JVI.65.9.4832-4838.1991. J Virol. 1991. PMID: 1714520 Free PMC article.

10

Passive immunization for the treatment and prevention of HIV infection.

Karwowska S, Zolla-Pazner S. Karwowska S, et al. Biotechnol Ther. 1991;2(1-2):31-48. Biotechnol Ther. 1991. PMID: 1845123 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

327 results

Search Page

Filters